

Resource Summary Report

Generated by [ASWG](#) on Aug 14, 2026

Oct3/4 Antibody, anti-human/mouse, APC, REAfinity™

RRID:AB_2819457

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-123-257, RRID:AB_2819457

Antibody Information

URL: http://antibodyregistry.org/AB_2819457

Proper Citation: Miltenyi Biotec Cat# 130-123-257, RRID:AB_2819457

Target Antigen: Oct3/4

Host Organism: human

Clonality: monoclonal

Antibody Name: Oct3/4 Antibody, anti-human/mouse, APC, REAfinity™

Description: This monoclonal targets Oct3/4

Target Organism: mouse, human

Clone ID: clone REA622

Antibody ID: AB_2819457

Vendor: Miltenyi Biotec

Catalog Number: 130-123-257

Record Creation Time: 20250819T235936+0000

Record Last Update: 20250820T070250+0000

Ratings and Alerts

No rating or validation information has been found for Oct3/4 Antibody, anti-human/mouse, APC, REAfinity™.

No alerts have been found for Oct3/4 Antibody, anti-human/mouse, APC, REAfinity™.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Luo Y, et al. (2026) CRISPR/Cas9 engineered and whole-genome characterized KIT D816V-mutant human iPSC lines. Stem cell research, 93, 103975.

Fernandez Vallone V, et al. (2025) Generation of 5 hiPSC lines from pediatric patients with Heritable pulmonary arterial hypertension (HPAH) caused by heterozygous mutations in the TBX4 gene. Stem cell research, 90, 103886.

Härting N, et al. (2025) Generation of hiPSC lines with fusion tagged thyroid hormone receptor ? isoforms to study isoform-specific actions of TR?1 and TR?2. Stem cell research, 86, 103720.

Ludwik KA, et al. (2025) Generation of two human induced pluripotent stem cell lines from Allan-Herndon-Dudley syndrome (AHDS) patients with SLC16A2:G401R or SLC16A2: H192R mutation. Stem cell research, 86, 103725.

Lewis K, et al. (2025) Generation of ten human induced pluripotent stem cell lines (hiPSCs) from patients with and without Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Post Chemotherapy Cognitive Impairment (PCCI). Stem cell research, 84, 103674.

Finke M, et al. (2025) Generation of four human induced pluripotent stem cell lines from functionally distinct T cell lineages with defined or undefined T cell receptor specificity. Stem cell research, 88, 103813.

Ludwik KA, et al. (2025) Correction of the Allan-Herndon-Dudley syndrome-causing SLC16A2 mutation G401R in a patient derived hiPSC line. Stem cell research, 85, 103698.

Ludwik KA, et al. (2025) Generation of human induced pluripotent stem cell line from an obesity patient with POMC deficiency due to POMC:W84X mutation. Stem cell research, 88, 103814.

Ludwik KA, et al. (2025) Generation of an isogenic iPSC line via CRISPR correction of the POMC:W84X mutation for monogenic obesity modeling. Stem cell research, 87, 103786.

Hernández D, et al. (2024) Generation of a gene-corrected human isogenic iPSC line from an Alzheimer's disease iPSC line carrying the PSEN1 H163R mutation. Stem cell research, 79, 103495.

Ludwik KA, et al. (2024) Generation of THRB-GS(E125G_G126S) and THRB-KO human iPSC lines to study noncanonical thyroid hormone signalling. Stem cell research, 74, 103275.

Aline Schmoll K, et al. (2024) Genome engineering of a neuronal specific, optogenetic, induced pluripotent stem cell line. Stem cell research, 75, 103317.

Ludwik KA, et al. (2024) Generation of two human induced pluripotent stem cell lines with BAX and BAK1 double knock-out using CRISPR/Cas9. Stem cell research, 76, 103377.

Ludwik KA, et al. (2023) Generation of iPSC lines with SLC16A2:G401R or SLC16A2 knock out. Stem cell research, 73, 103256.